{"title":"Oral switch vs. continued intravenous antibiotic therapy in patients with bacteraemia and sepsis: a systematic review and meta-analysis.","authors":"Qinyuan Li, Qi Zhou, Jiangbo Fan, Siyuan Huang, Yaolong Chen, Fujian Song, Zhou Fu, Enmei Liu, Daolin Tang, Ling Zeng, Zhengxiu Luo","doi":"10.1016/j.cmi.2024.11.035","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bacteraemia and sepsis have traditionally required continued intravenous (IV) antibiotics.</p><p><strong>Objectives: </strong>This study aims to evaluate if early transition to oral antibiotics is non-inferior to continued IV antibiotic therapy in treating patients with bacteraemia and sepsis.</p><p><strong>Data sources: </strong>Data sources include MEDLINE, Embase, Web of Science, the Cochrane Library, and Wanfang databases from inception to 13 July 2024, along with clinical trial registries and Google.com.</p><p><strong>Study eligibility criteria: </strong>Study eligibility criteria include randomized controlled trials (RCTs) and cohort studies.</p><p><strong>Participants: </strong>Participants include patients with bacteraemia and sepsis.</p><p><strong>Interventions: </strong>Interventions include early transition to oral antibiotics vs. continued IV antibiotics. Early oral switch was defined as 5-9 days for uncomplicated Staphylococcus aureus bacteraemia, <4 weeks for complicated S. aureus bacteraemia, 3-7 days for uncomplicated Streptococcus bacteraemia, and 3-5 days for uncomplicated Enterobacterales bacteraemia.</p><p><strong>Assessment of risk of bias: </strong>Assessment of risk of bias includes Cochrane risk of bias tool and Newcastle-Ottawa Scale.</p><p><strong>Methods of data synthesis: </strong>Random-effect models were used to pool the data. The primary outcome was treatment failure. The non-inferiority margin for treatment failure was 10%. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to rate the certainty of the evidence.</p><p><strong>Results: </strong>In total, 38 studies (6 RCTs, 10 adjusted cohorts, and 22 unadjusted cohorts) involving 11 566 patients were included. A primary analysis of 6 RCTs and 10 adjusted cohorts comprised 7102 patients. High-certainty evidence from six RCTs showed that early transition to oral antibiotics was non-inferior to continued IV therapy for treatment failure (n = 529; OR 0.89; 95% CI: 0.54-1.48). Low-certainty evidence from five adjusted cohorts also found no significant difference in treatment failure between the two groups (n = 929; OR 0.60; 95% CI: 0.29-1.72). Moderate-certainty evidence showed that oral switch therapy significantly reduced hospital stay (n = 2041; mean difference: -5.19 days; 95% CI: -8.16 to -2.22).</p><p><strong>Conclusions: </strong>Early transition to oral antibiotics was non-inferior to continued IV antibiotic treatment for bacteraemia and sepsis.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.11.035","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bacteraemia and sepsis have traditionally required continued intravenous (IV) antibiotics.
Objectives: This study aims to evaluate if early transition to oral antibiotics is non-inferior to continued IV antibiotic therapy in treating patients with bacteraemia and sepsis.
Data sources: Data sources include MEDLINE, Embase, Web of Science, the Cochrane Library, and Wanfang databases from inception to 13 July 2024, along with clinical trial registries and Google.com.
Study eligibility criteria: Study eligibility criteria include randomized controlled trials (RCTs) and cohort studies.
Participants: Participants include patients with bacteraemia and sepsis.
Interventions: Interventions include early transition to oral antibiotics vs. continued IV antibiotics. Early oral switch was defined as 5-9 days for uncomplicated Staphylococcus aureus bacteraemia, <4 weeks for complicated S. aureus bacteraemia, 3-7 days for uncomplicated Streptococcus bacteraemia, and 3-5 days for uncomplicated Enterobacterales bacteraemia.
Assessment of risk of bias: Assessment of risk of bias includes Cochrane risk of bias tool and Newcastle-Ottawa Scale.
Methods of data synthesis: Random-effect models were used to pool the data. The primary outcome was treatment failure. The non-inferiority margin for treatment failure was 10%. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to rate the certainty of the evidence.
Results: In total, 38 studies (6 RCTs, 10 adjusted cohorts, and 22 unadjusted cohorts) involving 11 566 patients were included. A primary analysis of 6 RCTs and 10 adjusted cohorts comprised 7102 patients. High-certainty evidence from six RCTs showed that early transition to oral antibiotics was non-inferior to continued IV therapy for treatment failure (n = 529; OR 0.89; 95% CI: 0.54-1.48). Low-certainty evidence from five adjusted cohorts also found no significant difference in treatment failure between the two groups (n = 929; OR 0.60; 95% CI: 0.29-1.72). Moderate-certainty evidence showed that oral switch therapy significantly reduced hospital stay (n = 2041; mean difference: -5.19 days; 95% CI: -8.16 to -2.22).
Conclusions: Early transition to oral antibiotics was non-inferior to continued IV antibiotic treatment for bacteraemia and sepsis.
期刊介绍:
Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.